CA3111057A1 - Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine - Google Patents

Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine Download PDF

Info

Publication number
CA3111057A1
CA3111057A1 CA3111057A CA3111057A CA3111057A1 CA 3111057 A1 CA3111057 A1 CA 3111057A1 CA 3111057 A CA3111057 A CA 3111057A CA 3111057 A CA3111057 A CA 3111057A CA 3111057 A1 CA3111057 A1 CA 3111057A1
Authority
CA
Canada
Prior art keywords
taurinamide
taurultam
composition
methylene glycol
neuroblastoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111057A
Other languages
English (en)
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of CA3111057A1 publication Critical patent/CA3111057A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Le neuroblastome est une tumeur affectant principalement l'enfant. La norme de soins actuelle n'est pas curative, sauf dans le cas rare d'une lésion résécable chirurgicalement, bien que des taux de survie aient été enregistrés pour un neuroblastome à faible risque et à risque modéré. La taurolidine a été mise au point en tant qu'anti-infectieux, mais on a découvert qu'elle possédait une étonnante activité oncolytique sur des cultures cellulaires et à présent sur un modèle de cancer de rongeur. L'efficacité sur le modèle de cancer de rongeur est supérieure à l'efficacité sur une culture cellulaire. L'invention concerne l'utilisation de produits d'hydrolyse de la taurolidine (taurultam et/ou taurinamide et/ou méthylène glycol et/ou des combinaisons choisies de ceux-ci) pour le traitement du neuroblastome chez des mammifères juveniles.
CA3111057A 2018-08-28 2019-08-28 Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine Pending CA3111057A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
US62/723,618 2018-08-28
PCT/US2019/048592 WO2020047113A1 (fr) 2018-08-28 2019-08-28 Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine

Publications (1)

Publication Number Publication Date
CA3111057A1 true CA3111057A1 (fr) 2020-02-05

Family

ID=69645349

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111057A Pending CA3111057A1 (fr) 2018-08-28 2019-08-28 Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine

Country Status (7)

Country Link
EP (1) EP3843746A4 (fr)
JP (1) JP2021535163A (fr)
KR (1) KR20210050544A (fr)
CN (1) CN113347976A (fr)
AU (1) AU2019330954A1 (fr)
CA (1) CA3111057A1 (fr)
WO (1) WO2020047113A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
AU784539B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Methods of treating tumors
CA2363973C (fr) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Amelioration de l'efficacite du 5-fluorouracil dans le traitement des metastases et du cancer
EP1442753B1 (fr) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition pour la prévention des infections par prothèses endovasculaires
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
EP1976531B1 (fr) * 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Compositions irradiees et traitement de cancers avec un rayonnement en combinaison avec la taurolidine et/ou le taurultam
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
JP2015512416A (ja) * 2012-03-30 2015-04-27 ノバルティス アーゲー 神経芽細胞腫、ユーイング肉腫または横紋筋肉腫の治療に使用するための化合物
CN108778339A (zh) * 2016-01-11 2018-11-09 科医公司 用于治疗神经母细胞瘤及其他癌症的治疗性纳米颗粒

Also Published As

Publication number Publication date
CN113347976A (zh) 2021-09-03
EP3843746A1 (fr) 2021-07-07
WO2020047113A1 (fr) 2020-03-05
EP3843746A4 (fr) 2022-10-19
KR20210050544A (ko) 2021-05-07
AU2019330954A1 (en) 2021-04-22
JP2021535163A (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
EP4062914A1 (fr) Utilisation d'un inhibiteur de fak dans la préparation d'un médicament pour le traitement de tumeurs présentant une mutation nras
Li et al. Anticancer therapy and lung injury: molecular mechanisms
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
KR20170131562A (ko) 암 약물과의 조합 요법에서의 nk-92 세포
KR20160021084A (ko) 사람에서 고형 종양의 치료를 위한 씨. 노비
Kerbel Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs
US20140294806A1 (en) Methods and compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
CA3111057A1 (fr) Traitement du neuroblastome avec des produits d'hydrolyse de taurolidine
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
JP2023549698A (ja) がんの治療のためのナノ粒子の組成物
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
Lallana et al. Update on the therapeutic approaches to brain tumors
CN113905764B (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
CA3111100A1 (fr) Traitement a la taurolidine pour des tumeurs exprimant des genes myc dans des corps de mammifere
Sesink The molecular and cellular consequences of AsiDNA™ combined with radiotherapy on healthy tissue
CN111788226A (zh) 溶酶体诱导的免疫原性细胞死亡的系统和方法
Buie et al. Current Treatment Options for the Management of Glioblastoma Multiforme.
Feher et al. Pilot trial of concomitant chemotherapy with paclitaxel and split‐course radiotherapy for very advanced squamous cell carcinoma of head and neck
Reda DEVELOPMENT OF NOVEL NANOPARTICLE BASED PLK1, EGFR, AND PD-L1 TARGETED THERAPIES FOR LUNG CANCER
Bunz Cancer Therapy
CN115137748A (zh) 介孔二氧化硅-氧化铈-miR129复合材料及其制备方法和应用
Marosi Drug therapy for recurrent, progressive, atypical, and malignant meningiomas
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
KR20070108933A (ko) 알부민 결합성 약물의 안전성 및 효능을 증가시키는 방법및 조성물